(VIANEWS) – MONTEA (MONT.BR), NAVAMEDIC (NAVA.OL), BAKKAFROST (BAKKA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MONTEA (MONT.BR)
25.8% sales growth and 5.79% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specialises in logistical property in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 30/09/2023 the property portfolio represented a total surface of 1,921,172 m² spread across 94 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €3.82.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 20.45. Meaning, the purchaser of the share is investing €20.45 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.79%.
More news about MONTEA.
2. NAVAMEDIC (NAVA.OL)
17.8% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.03. Meaning, the purchaser of the share is investing kr32.03 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 51.9%, now sitting on 502.65M for the twelve trailing months.
More news about NAVAMEDIC.
3. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products under the Bakkafrost and Havsbrún brands in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through four segments: Farming FO; Farming SCT; Value Added Products; and Fishmeal, Oil and Fish Feed. The company is involved in the breeding and on-growing of salmon; harvesting, sale, and distribution of salmon; salmon farming, harvest, filleting, sales, and administration; and production of skinless and boneless portions of salmon. It also produces and sells fishmeal, fish oil, and fish feed. In addition, it engages in production of styrofoam boxes, and biogas and fertilizer; and operates trading of fishes, lumpfish farming business, and freight transportation of goods, as well as produce and sell canned fish products. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr11.44.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 45.98. Meaning, the purchaser of the share is investing kr45.98 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 7.54B for the twelve trailing months.
More news about BAKKAFROST.
4. SALMAR (SALM.OL)
8.4% sales growth and 6.83% return on equity
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming, Sales & Industry, Icelandic Salmon, and SalMar Aker Ocean segments. It is involved in the broodstock, lumpfish, and smolt production activities; and marine-phase farming, harvesting, processing, and selling farmed salmon. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.
Earnings Per Share
As for profitability, SALMAR has a trailing twelve months EPS of kr6.52.
PE Ratio
SALMAR has a trailing twelve months price to earnings ratio of 90.71. Meaning, the purchaser of the share is investing kr90.71 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.83%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 36.3% and 90.5%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SALMAR’s EBITDA is 3.81.
Volume
Today’s last reported volume for SALMAR is 31121 which is 83.2% below its average volume of 185328.
More news about SALMAR.
5. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 22. Meaning, the purchaser of the share is investing kr22 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the ongoing quarter and 6.6% for the next.
Moving Average
VISTIN PHARMA’s value is under its 50-day moving average of kr23.11 and higher than its 200-day moving average of kr21.87.
Volume
Today’s last reported volume for VISTIN PHARMA is 3303 which is 85.27% below its average volume of 22430.
More news about VISTIN PHARMA.
